Why biotech is about to see M&A heat up
An M&A wave is coming in biotech. Plus, the U.S. vs. China: Who needs a deal more? … The Fed’s B.S. move… Time to buy small caps? … Buy these cryptos… And the next CoreWeave (CRWV)?
5 solid stocks trading at huge discounts
Disney (DIS) is in survival mode… Germany's big move… 5 beaten-down stocks to watch… Don't overlook this tech name... What's driving Autozone (AZO) higher? … This biotech stock's pullback is overdone… And a trade on tomorrow's crypto summit.
Apple is flashing major warning signs
What to expect from the "Magnificent 7" in 2024… The biggest risks to the market... Why you need to be extremely wary of Apple (AAPL)… And the left-for-dead sector poised to soar this year.
Why ‘hope’ is a horrible investment strategy
Andrew Horowitz of The Disciplined Investor explains why the Fed is hell-bent on hiking rates... Why you shouldn't pin your hopes on the Fed... and his advice for this market. Plus, Andrew's new fetish could make money in the metaverse.
A financial phenomenon you can’t afford to ignore…
Marc Lichtenfeld of The Oxford Club explains why the pullback is great for income investors... How to accelerate the compounding process—a phenomenon most investors ignore... How to find bonds for income... And a solid risk/reward setup in biotech.
Peak inflation is here… and I’ll tell you how to play it
The Fed bank stress test results... Signs inflation is peaking... And why the worst of the selloff is behind us. Plus, earnings red flags... and how to meet Frank in Las Vegas.
One biotech’s 80% single-day plunge: A case study for investors
Biotech Kodiak Sciences (KOD) plunged 80% in one day after a major drug trial setback. It’s a critical lesson on expectations… and the benefits of contrarian investing.
Get ready for the next “Roaring ’20s”
Genia shares why the economy is set to bounce back with a vengeance… three sectors to benefit from the recovery… and how to invest in “the Roaring ’20s 2.0” for maximum profit.
Why Pfizer is a better buy than Johnson & Johnson
In part three of David Cohne’s valuation series, he walks us through a comparison of two popular pharma stocks using five valuation metrics. Whenever you're deciding between two stocks to buy, keep this guide handy...
Did you buy these 5 tech stocks yet?
Genia highlights five of her best market calls... and why most are still fantastic buys at today’s levels. As you’ll see, it pays to follow Genia’s work…
Get ready for $100 silver prices
Keith Neumeyer, president and CEO of First Majestic Silver Corp., breaks down the current bull market in precious metals... why it could send silver over $100 per ounce... and some names he likes in the space. Plus: What you need…
You need exposure to this sector immediately
Rich Suttmeier, editor of 2-Second Trader, shares his thoughts on the market... his proprietary Black Box trading strategy... and where he sees the most opportunity in the market, both on the short and long sides. Plus, trillions will flow into…
3 market sectors to avoid during the coronavirus scare… and one innovative biotech to watch
The coronavirus puts certain companies at risk… but one biotech stock stands to benefit...
Search by
WAIT!
Your No–B.S. Guide to Wall Street Profits
Frank Curzio–30-year Wall Street veteran and market analyst–breaks down the mainstream media headlines, exposes the TRUTH about what’s really moving the markets, and brings you exclusive intel directly from Wall Street pros every week.
Follow Frank's
Wall Street Unplugged podcast
“I follow you. I’ve gotten amazing ideas for my shows from you.”
